What Are "Adrenaline Dumps" in POTS?
"Adrenaline dumps" is a colloquial term patients use to describe sudden episodes of intense sympathetic activation—characterized by abrupt surges in heart rate, palpitations, tremor, sweating, anxiety, and sometimes blood pressure spikes—that occur in the hyperadrenergic subtype of POTS. These episodes reflect excessive norepinephrine release or impaired reuptake, creating a state of sympathetic overactivity that drives the orthostatic tachycardia and associated symptoms 1, 2, 3.
Pathophysiology of Hyperadrenergic POTS
Hyperadrenergic POTS is defined by an increase in systolic blood pressure ≥10 mmHg during standing (with concomitant tachycardia) or serum norepinephrine levels ≥600 pg/mL upon standing 1.
The underlying mechanism involves excessive norepinephrine production or impaired reuptake, leading to sympathetic overactivity that manifests as both orthostatic tachycardia and episodic surges of adrenergic symptoms 3, 4.
Recent evidence demonstrates that hyperadrenergic POTS patients exhibit enhanced peripheral sympathetic neurovascular transduction—meaning their blood vessels are hyper-responsive to normal levels of sympathetic nerve activity, amplifying the cardiovascular response 5.
This enhanced neurovascular transduction results in higher baseline systolic blood pressure (118 ± 10 vs 105 ± 12 mmHg in non-hyperadrenergic POTS), shorter pressure recovery times, and exaggerated blood pressure responses despite comparable sympathetic nerve activity levels 5.
The hyperadrenergic state is a primary driver of orthostatic tachycardia, not merely a compensatory response 2.
Clinical Presentation of "Adrenaline Dumps"
Patients describe these episodes as sudden waves of:
- Palpitations and forceful heartbeat 6
- Tremulousness and shakiness 7
- Sweating 6
- Anxiety, apprehension, or nervousness 6
- Dizziness and lightheadedness 6
- Nausea 6
- Chest discomfort or pressure 8
- Shortness of breath 8
These symptoms typically worsen upon standing and improve with recumbence, distinguishing them from panic attacks or paroxysmal supraventricular tachycardia, which occur independent of posture 7.
Diagnostic Identification of Hyperadrenergic POTS
Office-Based Screening
Perform the 10-minute active stand test: after 5 minutes supine, measure heart rate and blood pressure at 1,3,5, and 10 minutes of standing 7.
Hyperadrenergic POTS is identified by a systolic blood pressure increase ≥10 mmHg during standing (in addition to meeting standard POTS tachycardia criteria) 1.
Alternatively, serum norepinephrine ≥600 pg/mL upon standing confirms the hyperadrenergic phenotype, though this test is not routinely recommended 1.
Advanced Marker (Research-Validated)
A Valsalva phase 2 diastolic blood pressure rise ≥15 mmHg serves as a clinical sympathetic marker and identifies hyperadrenergic POTS with high correlation to sympathetic nerve activity 5.
This cutoff separates hyperadrenergic from non-hyperadrenergic POTS and reflects enhanced neurovascular transduction rather than simply elevated sympathetic tone 5.
Management of Hyperadrenergic POTS & "Adrenaline Dumps"
Non-Pharmacologic Foundation (Mandatory for All Patients)
Semi-recumbent aerobic exercise (rowing, recumbent bike, swimming) ≥4 sessions per week, ≥30 minutes each, is the cornerstone of therapy and the only intervention with evidence for achieving remission 9.
Increase fluid intake to ≥3 L daily and sodium to ≈10 g daily to expand plasma volume 9.
Waist-high compression stockings (20–30 mmHg) or abdominal binders reduce venous pooling; compression below the thighs is ineffective 9.
Avoid warm environments, prolonged standing, and triggers such as large meals and rapid postural changes 9.
Pharmacologic Therapy (Phenotype-Directed)
For hyperadrenergic POTS specifically:
Low-dose propranolol 10–20 mg four times daily is the first-line agent, reducing standing heart rate, controlling palpitations and tremor, and improving exercise capacity 10, 9.
Avoid higher doses or long-acting formulations, which lower heart rate without symptom relief and worsen fatigue, undermining adherence to exercise programs 9.
Central sympatholytic agents (clonidine 0.1–0.2 mg up to three times daily or methyldopa starting 125 mg at bedtime, titrated to 250 mg twice daily) improve palpitations, tremor, and blood pressure surges in hyperadrenergic patients 9.
Do not use these agents if any degree of orthostatic hypotension or relative supine hypotension is present; monitor for sedation and dry mouth 9.
Avoid norepinephrine reuptake inhibitors (SNRIs, tricyclic antidepressants, atomoxetine), as they exacerbate the hyperadrenergic state 7, 3.
Agents to Avoid in Hyperadrenergic POTS
Midodrine is contraindicated in hyperadrenergic patients with hypertension, as it offers minimal benefit and may worsen blood pressure 9.
Fludrocortisone should not be used in patients with migraine (common in POTS), as it increases migraine frequency 10.
Treatment Algorithm for Hyperadrenergic POTS
Initiate non-pharmacologic measures immediately: semi-recumbent exercise, compression garments, increased salt/fluid intake 9.
If disabling "adrenaline dump" episodes persist despite 4–6 weeks of non-pharmacologic therapy, add low-dose propranolol 10–20 mg four times daily 10, 9.
If propranolol is insufficient or poorly tolerated (e.g., worsening fatigue, asthma), switch to or add a central sympatholytic agent (clonidine or methyldopa) 9.
For refractory cases, consider adding pyridostigmine to a β-blocker to reduce orthostatic tachycardia via enhanced synaptic acetylcholine; anticipate diarrhea as a frequent adverse effect 9.
Reserve ivabradine 2.5–7.5 mg twice daily for β-blocker non-responders or intolerance, as it selectively lowers heart rate without negative inotropic effects 9.
Continue non-pharmacologic measures alongside any pharmacologic regimen; medications serve as a bridge during early exercise phases when symptoms limit participation 9.
Common Pitfalls
Do not diagnose hyperadrenergic POTS without objective documentation of blood pressure increase ≥10 mmHg or elevated standing norepinephrine 1.
Do not confuse hyperadrenergic POTS with panic disorder; the key distinction is mandatory positional dependence (symptoms worsen on standing, improve when lying down) 7.
Do not use high-dose or long-acting propranolol formulations, which worsen fatigue and reduce exercise tolerance without improving symptoms 9.
Do not overlook medication-induced sympathetic activation; always review current medications for stimulants, SNRIs, tricyclics, and MAOIs 7.
Recognize that hyperadrenergic POTS patients are usually refractory to first-line treatments and often require multiple medication combinations 1.
Evidence Quality & Clinical Context
All pharmacologic recommendations are based on small acute randomized trials or retrospective series; no long-term randomized controlled trials exist, resulting in low-to-moderate quality evidence 9, 11, 12.
Hyperadrenergic POTS represents approximately 9% of POTS cases (27 of 300 patients in one autonomic center series), is predominantly female (89%), and is typically more difficult to treat than other POTS subtypes 1.
The term "adrenaline dumps" is patient-generated language for episodic surges of sympathetic activation superimposed on chronic hyperadrenergic tone; clinicians should recognize this terminology and translate it into the formal diagnosis of hyperadrenergic POTS 1, 2, 3.